Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 4/2016

01-04-2016 | Original Article

Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients

Authors: Seong-Jang Kim, Phillip J. Koo, Samuel Chang

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2016

Login to get access

Abstract

Introduction

The goal of the current study was to investigate the predictive and prognostic values of repeated F-18 FDG PET/CT parameter changes for prediction of complete pathologic response (pCR) in patients with adenocarcinoma of locally advanced esophageal cancer (LAEC) who received preoperative concurrent chemoradiotherapy (PCRT).

Methods

A total 53 patients with LAEC patients were included in the current study. All patients were evaluated by F-18 FDG PET/CT before and during chemoradiotherapy. The percent changes (∆, %) in F-18 FDG PET/CT parameters were used to predict pCR and to calculate overall survival (OS). The predictive value for pCR of F-18 FDG PET/CT cutoff values was determined by ROC analysis. The prognostic significance was assessed using Kaplan–Meier analysis.

Results

pCR occurred in 15 patients (28.3 %). When ΔSUVmax > 23.5 % was used as cutoff, the sensitivity and specificity of F-18 FDG PET/CT for prediction of pCR were 100 % and 52.6, respectively. The AUC was 0.750 (95 % CI; 0.612–0.859), and standard error (SE) was 0.0633 (p = 0.0002). ΔMTV resulted in 80 % sensitivity, 76.3 % specificity, and 0.731 AUC (95 % CI; 0.591–0.843, SE = 0.077, p = 0.0027) for cutoff values >25.5 %. When ΔTLG > 44.8 % was used as cutoff, the sensitivity and specificity of F-18 FDG PET/CT for prediction of pCR were 100 and 65.8 %, respectively. The AUC was 0.893 (95 % CI; 0.777–0.961), and SE was 0.0431 (p < 0.0001). Kaplan–Meier analysis showed that high ΔSUVmax, ΔMTV, and ΔTLG were associated with improved OS.

Conclusion

In conclusion, the current study shows the capability of the changes (Δ) in repeated F-18 FDG PET/CT parameters to predict the achievement of pCR during PCRT in LAEC patients. Among the parameters, the ΔSUVmax, ΔMTV, and ΔTLG were predictors for pCR and well associated with OS.
Literature
1.
3.
go back to reference Panting AZ, Gossage JA, Mamidanna R, Newman G, Robinson A, Manifold DK, Hale PC (2011) Outcomes from chemoradiotherapy for patients with esophageal cancer. Dis Esophagus 24(3):172–176CrossRef Panting AZ, Gossage JA, Mamidanna R, Newman G, Robinson A, Manifold DK, Hale PC (2011) Outcomes from chemoradiotherapy for patients with esophageal cancer. Dis Esophagus 24(3):172–176CrossRef
4.
go back to reference Pennathur A, Gibson MK, Jobe BA, Luketich JD (2013) Oesophageal carcinoma. Lancet 381(9864):400–412CrossRefPubMed Pennathur A, Gibson MK, Jobe BA, Luketich JD (2013) Oesophageal carcinoma. Lancet 381(9864):400–412CrossRefPubMed
5.
go back to reference Pöttgen C, Stuschke M (2012) Radiotherapy versus surgery within multimodality protocols for easophaeal cancer- a meta-analysis of the randomized trials. Cancer Treat Rev 38(6):599–604CrossRefPubMed Pöttgen C, Stuschke M (2012) Radiotherapy versus surgery within multimodality protocols for easophaeal cancer- a meta-analysis of the randomized trials. Cancer Treat Rev 38(6):599–604CrossRefPubMed
6.
go back to reference Kranzfelder M, Schuster T, Geinitz H, Friess H, Buchler P (2011) Meta-analysis of neoadjuvant treatment modalities and definitive nonsurgical therapy for osophageal squamous cell cancer. Br J Surg 98(6):768–783CrossRefPubMed Kranzfelder M, Schuster T, Geinitz H, Friess H, Buchler P (2011) Meta-analysis of neoadjuvant treatment modalities and definitive nonsurgical therapy for osophageal squamous cell cancer. Br J Surg 98(6):768–783CrossRefPubMed
7.
go back to reference van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group (2012). Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084 van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group (2012). Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084
8.
go back to reference Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SCrossRefPubMedPubMedCentral Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SCrossRefPubMedPubMedCentral
9.
go back to reference Flamen P, Lerut A, van Custem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18(18):3202–3210PubMed Flamen P, Lerut A, van Custem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18(18):3202–3210PubMed
10.
go back to reference Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Kuwano H, Oriuchi N, Endo K (2005) The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal cancer. Cancer 103(1):148–156CrossRefPubMed Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Kuwano H, Oriuchi N, Endo K (2005) The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal cancer. Cancer 103(1):148–156CrossRefPubMed
11.
go back to reference Ott K, Weber W, Siewert JR (2006) The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus 19(6):433–442CrossRefPubMed Ott K, Weber W, Siewert JR (2006) The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus 19(6):433–442CrossRefPubMed
12.
go back to reference Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY, Park SI, Kim YH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH (2007) Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43(9):1385–1391CrossRefPubMed Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY, Park SI, Kim YH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH (2007) Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43(9):1385–1391CrossRefPubMed
13.
go back to reference Huang JW, Yeh HL, Hsu CP, Lu YY, Chuang CY, Lin JC, Lin JF, Chang CF (2015) To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan. J Chin Med Assoc 78(4):229–234CrossRefPubMed Huang JW, Yeh HL, Hsu CP, Lu YY, Chuang CY, Lin JC, Lin JF, Chang CF (2015) To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan. J Chin Med Assoc 78(4):229–234CrossRefPubMed
14.
go back to reference Miyata H, Yamasaki M, Takahashi T, Murakami K, Tanaka K, Yukinori K, Nakajima K, Takiguchi S, Morii E, Hatazawa J, Mori M, Doki Y (2014) Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET). Ann Surg Oncol 21(2):575–582CrossRefPubMed Miyata H, Yamasaki M, Takahashi T, Murakami K, Tanaka K, Yukinori K, Nakajima K, Takiguchi S, Morii E, Hatazawa J, Mori M, Doki Y (2014) Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET). Ann Surg Oncol 21(2):575–582CrossRefPubMed
15.
go back to reference van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ (2011) Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 253(1):56–63CrossRefPubMed van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ (2011) Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 253(1):56–63CrossRefPubMed
16.
go back to reference Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A (2012) The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma. J Gastrointest Cancer 43(4):612–618CrossRefPubMed Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A (2012) The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma. J Gastrointest Cancer 43(4):612–618CrossRefPubMed
17.
go back to reference Malik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M, Gillham C, Reynolds JV (2010) Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med 51(12):1863–1869CrossRefPubMed Malik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M, Gillham C, Reynolds JV (2010) Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med 51(12):1863–1869CrossRefPubMed
18.
go back to reference Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA (2015) 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer 51(17):2545–2552CrossRefPubMed Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA (2015) 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer 51(17):2545–2552CrossRefPubMed
19.
go back to reference Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C (2013) Ineffectiveness of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 258(1):66–76CrossRefPubMed Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C (2013) Ineffectiveness of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 258(1):66–76CrossRefPubMed
20.
go back to reference Kwee RM (2010) Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology 254(3):707–717CrossRefPubMed Kwee RM (2010) Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology 254(3):707–717CrossRefPubMed
21.
go back to reference Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J (2011) Prognostic significance of metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer 73(3):332–337CrossRefPubMed Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J (2011) Prognostic significance of metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer 73(3):332–337CrossRefPubMed
22.
go back to reference Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, Price R, Patrikeos AP, Musk AW, Millward MJ (2007) Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 48(9):1449–1458CrossRefPubMed Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, Price R, Patrikeos AP, Musk AW, Millward MJ (2007) Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 48(9):1449–1458CrossRefPubMed
23.
go back to reference Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, Ahn MJ, Kim TS, Yi CA, Chung MJ (2010) Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 17(10):2787–2794CrossRefPubMed Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, Ahn MJ, Kim TS, Yi CA, Chung MJ (2010) Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 17(10):2787–2794CrossRefPubMed
24.
go back to reference Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z, Gong H, Li B (2014) Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med 55(10):1584–1590CrossRefPubMed Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z, Gong H, Li B (2014) Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med 55(10):1584–1590CrossRefPubMed
25.
go back to reference Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA (2008) Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol 89(3):278–286CrossRefPubMed Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA (2008) Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol 89(3):278–286CrossRefPubMed
26.
go back to reference Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW Jr, Koong AC, Chang DT (2012) Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys 84(2):471–477CrossRefPubMed Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW Jr, Koong AC, Chang DT (2012) Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys 84(2):471–477CrossRefPubMed
27.
go back to reference Carvalho S, Leijenaar RT, Velazquez ER, Oberije C, Parmar C, van Elmpt W, Reymen B, Troost EG, Oellers M, Dekker A, Gillies R, Aerts HJ, Lambin P (2013) Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer. Acta Oncol 52(7):1398–1404CrossRefPubMedPubMedCentral Carvalho S, Leijenaar RT, Velazquez ER, Oberije C, Parmar C, van Elmpt W, Reymen B, Troost EG, Oellers M, Dekker A, Gillies R, Aerts HJ, Lambin P (2013) Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer. Acta Oncol 52(7):1398–1404CrossRefPubMedPubMedCentral
28.
go back to reference Capirci C, Rubello D, Chierichetti F, Crepaldi G, Fanti S, Mandoliti G, Salviato S, Boni G, Rampin L, Polico C, Mariani G (2006) Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. Am J Roentgenol 187(2):W202–W208CrossRef Capirci C, Rubello D, Chierichetti F, Crepaldi G, Fanti S, Mandoliti G, Salviato S, Boni G, Rampin L, Polico C, Mariani G (2006) Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. Am J Roentgenol 187(2):W202–W208CrossRef
29.
go back to reference Huh JW, Min JJ, Lee JH, Lee JH, Kim HR, Kim YJ (2012) The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation. Am J Clin Oncol 35(4):340–344CrossRefPubMed Huh JW, Min JJ, Lee JH, Lee JH, Kim HR, Kim YJ (2012) The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation. Am J Clin Oncol 35(4):340–344CrossRefPubMed
30.
go back to reference Capirci C, Rubello D, Pasini F, Galeotti F, Bianchini E, Del Favero G, Panzavolta R, Crepaldi G, Rampin L, Facci E, Gava M, Banti E, Marano G (2009) The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. Int J Radiat Oncol Biol Phys 74(5):1461–1469CrossRefPubMed Capirci C, Rubello D, Pasini F, Galeotti F, Bianchini E, Del Favero G, Panzavolta R, Crepaldi G, Rampin L, Facci E, Gava M, Banti E, Marano G (2009) The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. Int J Radiat Oncol Biol Phys 74(5):1461–1469CrossRefPubMed
31.
go back to reference Smithers BM, Couper GC, Thomas JM, Wong D, Gotley DC, Martin I, Harvey JA, Thomson DB, Walpole ET, Watts N, Burmeister BH (2008) Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus 21(2):151–158CrossRefPubMed Smithers BM, Couper GC, Thomas JM, Wong D, Gotley DC, Martin I, Harvey JA, Thomson DB, Walpole ET, Watts N, Burmeister BH (2008) Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus 21(2):151–158CrossRefPubMed
32.
go back to reference Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R (1999) Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2(3):159–171CrossRefPubMed Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R (1999) Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2(3):159–171CrossRefPubMed
33.
go back to reference Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, Hyun SH, Park K, Ahn MJ, Ahn YC, Kim HJ, Ko YH, Baek CH (2009) Metabolic tumor volume of [18F]-Fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 15(18):5861–5868CrossRefPubMed Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, Hyun SH, Park K, Ahn MJ, Ahn YC, Kim HJ, Ko YH, Baek CH (2009) Metabolic tumor volume of [18F]-Fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 15(18):5861–5868CrossRefPubMed
34.
go back to reference Stiekema J, Vermeulen D, Vegt E, Voncken FE, Aleman BM, Sanders J, Boot H, van Sandick JW (2014) Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer. Clin Nucl Med 39(10):862–867CrossRefPubMed Stiekema J, Vermeulen D, Vegt E, Voncken FE, Aleman BM, Sanders J, Boot H, van Sandick JW (2014) Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer. Clin Nucl Med 39(10):862–867CrossRefPubMed
Metadata
Title
Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients
Authors
Seong-Jang Kim
Phillip J. Koo
Samuel Chang
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-2988-8

Other articles of this Issue 4/2016

Cancer Chemotherapy and Pharmacology 4/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine